Indium (In-111)oxinat Curium Netherlands

Indium-111 oxine, the active ingredient in Indium (In-111)oxinat Curium Netherlands, is a radiopharmaceutical presented as a sterile solution for injection for intravenous use. It selectively binds to circulating leukocytes, allowing gamma‑camera visualization of infection and inflammation sites in adult and pediatric patients undergoing diagnostic evaluation. The radiolabelled compound provides high‑resolution images that assist clinicians in locating abscesses, assessing fever of unknown origin, and guiding therapeutic decisions.

GNH USA supplies Indium (In-111)oxinat Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and clinics worldwide.

Indium-111 oxine is used in nuclear medicine imaging to detect infection and inflammation. - Detection of infection and inflammation: Provides gamma‑camera images that locate bacterial or inflammatory sites throughout the body, supporting diagnosis. - Localization of abscesses: Highlights collections of pus, enabling precise surgical or percutaneous drainage planning. - Evaluation of fever of unknown origin: Identifies occult infectious or inflammatory sources when routine investigations fail to reveal a cause.

Adverse reactions to indium‑111 oxine are generally related to the radiopharmaceutical nature of the preparation and the injection procedure.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness. - Transient fever: low‑grade temperature rise shortly after administration. - Headache: mild headache occurring within hours. - Flushing: brief sensation of warmth or redness.

Serious or Rare Side Effects: - Allergic reaction: urticaria, rash, or anaphylaxis requiring immediate medical attention. - Severe neutropenia: marked reduction in white blood cell count. - Radiation‑induced tissue injury: localized damage at high cumulative doses. - Hemolysis: breakdown of red blood cells. - Cardiac arrhythmia: abnormal heart rhythm in susceptible patients.

When using indium‑111 oxine, clinicians should observe specific precautions to ensure patient safety and product integrity. - Patient selection: assess for hypersensitivity to radiopharmaceuticals before administration. - Pregnancy: avoid use unless benefits outweigh potential fetal radiation exposure. - Breastfeeding: discontinue nursing for an appropriate period after dosing. - Renal function: evaluate kidney function as excretion may be altered in impairment. - Concomitant therapies: consider interactions with other nuclear medicine agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium‑111 oxine may interact with other substances that affect radiopharmaceutical distribution or patient safety.

Major Interactions (Avoid): - Chemotherapeutic agents: may alter leukocyte kinetics and reduce imaging accuracy. - High‑dose steroids: suppress leukocyte migration, compromising target localization.

Moderate Interactions (Monitor Closely): - Other radiopharmaceuticals: concurrent administration can cause overlapping radiation exposure. - Anticoagulants: increase risk of bleeding at injection site. - Immunosuppressants: may affect leukocyte function and image quality. - Contrast agents: timing should be spaced to avoid interference with gamma detection.